Evotec Announces CSO Dr. Cord Dohrmann's Departure
News related to:Evotec SE · 2 min read
HAMBURG, Germany, Sept. 29, 2026 /CourierPR/ -- Evotec, a life science company pioneering drug discovery and development, announced that Dr. Cord Dohrmann, the Chief Scientific Officer (CSO) and a member of the Management Board, will step down as of September 30, 2026. The decision was made through mutual consent between Dohrmann and the company.
Dr. Christian Wojczewski, the Chief Executive Officer of Evotec, expressed gratitude for Dohrmann's contributions over the past 16 years.
Evotec, with a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. The company operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Evotec works with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Its global team of around 4,500 experts supports a wide range of services and programs.
The search for Dohrmann's successor is ongoing. Evotec remains committed to its mission of accelerating the journey from concept to cure, faster, smarter, and with greater precision.
The company's commitment to scientific excellence and innovation has been a cornerstone of its success. Dohrmann's departure marks a significant transition in the leadership of Evotec's scientific direction. The company's robust science infrastructure, built over the past 16 years, will continue to drive its future growth and profitability.
Dr. Dohrmann's contributions have been instrumental in shaping Evotec's strategic vision and operational capabilities. His expertise in emerging technologies and future scientific trends has been crucial in establishing key capabilities across the company's platforms. The iPSC-based technologies and omics capabilities, in particular, have played a significant role in reinforcing Evotec's scientific leadership.
As Evotec looks to the future, the company is committed to maintaining its position as a leader in drug discovery and development. The search for a new CSO is a testament to the company's ongoing commitment to innovation and excellence. The company's global team of experts will continue to support a wide range of services and programs, ensuring that Evotec remains at the forefront of scientific research and development.
The company's strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, underscores its commitment to innovation and collaboration. Evotec's global presence, with sites in Europe and the U.S., allows for a diverse range of services and programs, supporting a wide array of stakeholders, including Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders.
In summary, Dr. Cord Dohrmann's departure from his role as Chief Scientific Officer marks a significant transition in Evotec's leadership. The company remains committed to its mission of accelerating the journey from concept to cure, faster, smarter, and with greater precision. The search for a successor is ongoing, and the company is confident in its ability to continue driving scientific excellence and innovation.